Mayne Pharma

Name

Mayne Pharma

Legal name

Mayne Pharma Group Limited

Website

https://maynepharma.com

Company type

Public

Founded year

1980

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Salisbury

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Specialty Pharmaceutical Product Sales: Mayne Pharma generates revenue primarily through the sale of branded and generic pharmaceuticals in the US and Australia, including women's health products (contraceptives, menopause treatments) and dermatology products (treatments for psoriasis, acne, rosacea). Products are sold through direct-to-patient channels (DistributeRx) and traditional wholesale/distribution channels.
2. Contract Development and Manufacturing (CDMO Services): Mayne Pharma operates a full-service contract development and manufacturing organisation (CDMO) providing pharmaceutical development, analytical testing, and commercial manufacturing services to clients worldwide. Revenue is generated through service fees for development and manufacturing.
3. Out-licensing and In-licensing Royalties: Mayne Pharma develops partnerships for global marketing of products developed in-house, receiving licensing fees and royalties from international partners for products including LOZANOC®/TOLSURA®, KAPANOL®, ERYC®, and ASTRIX® marketed in various countries.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Core offering

Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops, manufactures, and commercializes branded and generic prescription drugs across women's health, dermatology, infectious disease, and pain management. The company applies proprietary oral and topical drug delivery technologies (SUBA®, Pellet, CLEANTASTE®, Controlled Release) to enhance bioavailability and patient outcomes, operates a direct-to-patient distribution platform (DistributeRx) in the US, and provides CDMO contract development and manufacturing services globally.

Product overview

Mayne Pharma is a specialty pharmaceutical company with a diversified portfolio spanning Women's Health, Dermatology, and Infectious Disease therapeutic areas. The company's product offerings include branded prescription drugs (such as ANNOVERA®, BIJUVA®, IMVEXXY®, DORYX®, LEXETTE®, RHOFADE®) and generic pharmaceuticals, supported by proprietary drug delivery technologies including SUBA® bioavailability enhancement, Pellet Technology, CLEANTASTE® taste masking, and Controlled Release Delivery Systems. The company operates DistributeRx, a direct-to-patient distribution platform, and provides CDMO contract manufacturing services. Products are commercialized in the US, Australia, and international markets through strategic partnerships.

Differentiator

Problem solved

Functional benefit

Brands

• Adelaide Apothecary: Pharmacy licensed in all 50 US states supporting the DistributeRx direct-to-patient model
• DistributeRx
• Mayne Pharma Services

Products and services

• ANNOVERA® Vaginal System Segesterone Acetate and Ethinyl Estradiol Vaginal System providing sustained-release contraception over multiple cycles; targeted at women in the US seeking long-acting hormonal contraception.
• BIJUVA® Capsules (1 mg/100 mg) Estradiol and Progesterone Capsules for menopausal hormone therapy, providing bioidentical hormone replacement for women experiencing menopausal symptoms.
• BIJUVA® Capsules (0.5 mg/100 mg) Lower-dose Estradiol and Progesterone Capsules for menopausal hormone therapy, providing bioidentical hormone replacement.
• IMVEXXY® Vaginal Inserts (10 mcg) Estradiol Vaginal Insert (10 mcg) for treatment of dyspareunia due to vulvar and vaginal atrophy in menopausal women.
• IMVEXXY® Vaginal Inserts (4 mcg) Estradiol Vaginal Insert (4 mcg) for treatment of dyspareunia due to vulvar and vaginal atrophy in menopausal women.
• NEXTSTELLIS® Tablets Drospirenone and Estetrol Tablets (3 mg/14.2 mg) for oral contraception using a novel estrogen component; available in the US and Australia.
• SOLTAMOX® Oral Solution Tamoxifen Citrate Oral Solution for treatment of breast cancer, providing a liquid alternative to tablet formulations.
• DORYX® MPC Delayed-Release Tablets Doxycycline Hyclate Delayed-Release Tablets, 60 mg for acne treatment using proprietary pellet technology.
• DORYX® Delayed-Release Tablets (200 mg) Doxycycline Hyclate Delayed-Release Tablets, 200 mg for acne and bacterial infections, leveraging pellet technology.
• FABIOR® Foam Tazarotene Foam, 0.1% for topical treatment of acne vulgaris.
• LEXETTE® Topical Foam Halobetasol Propionate Topical Foam, 0.05% for treatment of plaque psoriasis.
• RHOFADE® Cream Oxymetazoline Hydrochloride Cream, 1% for topical treatment of persistent facial erythema associated with rosacea.
• SORILUX® Foam Calcipotriene Foam, 0.005% for treatment of plaque psoriasis.
• WYNZORA® Cream Calcipotriene and Betamethasone Dipropionate Cream for treatment of plaque psoriasis.
• EPSOLAY® Cream Benzoyl Peroxide Cream, 5% 30g Pump for treatment of rosacea.
• TWYNEO® Cream Tretinoin and Benzoyl Peroxide Cream, 0.1%/3% for treatment of acne vulgaris.
• TOLSURA® Capsules SUBA®-Itraconazole Capsules, 65 mg using proprietary SUBA bioavailability technology for enhanced antifungal absorption; marketed in the US.
• LOZANOC® / TOLSURA® Capsules (Rest of World) Orally administered antifungal agent using SUBA technology with approximately double the bioavailability of conventional itraconazole formulations; marketed internationally through licensing partners.
• ERYC® Capsules Delayed-release erythromycin using proprietary pellet technology, protecting the drug from stomach acid for optimal intestinal absorption.
• KAPANOL® Capsules Sustained-release morphine sulfate capsules (10 mg, 20 mg, 50 mg, 100 mg) for management of moderate to severe chronic pain.
• ASTRIX® Capsules Enteric-coated pelletized low-dose aspirin for prevention of heart attack and stroke, reducing stomach irritation compared to immediate-release aspirin.
• DistributeRx Direct-to-patient pharmaceutical distribution platform bypassing intermediaries, utilizing Adelaide Apothecary pharmacy (licensed in all 50 US states) and contracted specialty pharmacies; approximately 70-80% of prescriptions expected through cash-pay Adelaide channel.
• CDMO Contract Development and Manufacturing Services Full-service contract development and manufacturing organization specializing in novel oral and topical dose forms, providing pharmaceutical development, analytical testing, and commercial manufacturing services to clients worldwide.

Quantifiable outcome

• H1 FY26 gross margin improved to 65.3%, up 390 basis points, driven by strategic shift toward higher-margin dermatology products and direct-to-patient channels
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Resilia PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 June 2026DistributerRx (wholly-owned subsidiary of Mayne Pharma) secured an exclusive distribution partnership with Atlanta-based Resilia Pharmaceuticals to distribute RECEDO topical gel across the United States. DistributerRx leverages its digital prescription distribution platform and receives structured fixed fees per prescription filled. The partnership targets specialist healthcare prescribers in plastic surgery and OB/GYN practices for advanced scar care.
• BoryungminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships of products developed in-house.
• ISDINminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships.
• GaldermaminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships.
• Gedeon Richter (formerly Mithra)minorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships.
• ViatrisminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy.
• LipomedminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy.
• TXMD (TherapeuticsMD)minorStrategic or Co-development PartnerListed as an existing partner. TherapeuticsMD reported license revenue surging 71.6% to $3.0 million primarily driven by sales of licensed products under the Mayne License Agreement, with $7.5 million cash as of December 31, 2025.
• Upsher-SmithminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy.
• SandozminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy.
• Mc2minorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy.
• CoAssistcoreTechnology or IntegrationVendor partner for benefits verification in the DistributeRx direct-to-patient distribution model. CoAssist supports the digital prescription platform by verifying patient insurance benefits.
• International Licensing Partners (Argentina, Austria, Germany, Israel, Italy, Mexico, Spain, Middle East)minorChannel Partner/ Reseller/ DistributorMayne Pharma has established international partners for LOZANOC®/TOLSURA® in Argentina, Austria, Germany, Israel, Italy, Mexico, Spain, and the Middle East for out-licensing of products developed in-house.
• KAPANOL® International Partners (Thailand, Canada, Switzerland, Germany, Austria, Slovenia, Bulgaria)minorChannel Partner/ Reseller/ DistributorKAPANOL® capsules are partnered internationally in Thailand, Canada, Switzerland, Germany, Austria, Slovenia, Bulgaria with options to extend in the rest of Europe and the United Kingdom.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Catalent: Large global CDMO offering oral, injectable and biologic manufacturing services. Comparable to Mayne Pharma Services in CDMO scope but with much broader capabilities and client base.
• Patheon (Thermo Fisher Scientific): Integrated CDMO providing drug substance through commercial manufacturing for small molecules and biologics. Comparable to Mayne in offering development and commercial-scale manufacturing under one roof.
• Teva Pharmaceutical Industries: Global leader in generic and specialty pharmaceuticals with substantial women's health and dermatology portfolios. Comparable in specialty/generic mix and CDMO-adjacent manufacturing scale.
• Endo International: Specialty pharma with diversified portfolio across branded, sterile injectables and generics. Comparable in operating a specialty-focused model with US commercial scale.
• Apotex: Canadian generic pharmaceutical manufacturer with diversified portfolio and in-house development. Comparable in scale and generic/specialty combination, though primarily Canadian-headquartered.

Direct peers

• Perrigo Company: Specialty generics and OTC pharmaceutical company with broad dermatology presence. Comparable to Mayne in combining generic and branded dermatology franchises.
• TherapeuticsMD: Women's health specialty pharma commercialising ANNOVERA, BIJUVA and IMVEXXY (licensed from Mayne). Directly comparable in US women's reproductive and menopause product portfolio.
• Hovione: Mid-sized CDMO specialising in oral solid dose development and manufacturing with proprietary particle engineering platforms. Closely comparable to Mayne's CDMO business in scale and dose-form focus.
• Cosette Pharmaceuticals: US specialty generics company that pursued Mayne's acquisition. Most directly comparable US specialty generics peer with overlapping portfolio and CDMO-style manufacturing capabilities.

Regional players

• Aspen Pharmacare: South Africa-based specialty and generic pharma with strong emerging-market franchise. Comparable in specialty pharma focus and global partnership approach, though geographically different.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/12253

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mayne Pharma